Anhui Sinobioway Medicine

Anhui Sinobioway Medicine Co., Ltd. is a China-based biopharmaceutical company focused on the development and commercialization of biologics and chemical drugs. The company's flagship product is Recombinant Human Interferon α2b, marketed through its subsidiary Xiamen Sinobioway Biotech, which is used extensively in treating viral infections like Hepatitis B and C, as well as various oncological conditions. Beyond biologics, the company maintains a portfolio of chemical pharmaceuticals and traditional Chinese medicines. Sinobioway operates integrated manufacturing facilities and is listed on the Shenzhen Stock Exchange. The company has historically been part of the Peking University Sinobioway Group, positioning it as a key player in China's high-tech medical sector. It also holds significant historical and legal ties to Sinovac Biotech, which has been a point of strategic focus and corporate dispute.